Compare Progressive Corp (PGR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Progressive Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Progressive Corp trades at $218.13 (market cap $126.95B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: Progressive Corp is far larger — about 12.6× State Street SPDR S&P Biotech ETF's market cap, and Progressive Corp pays a 0.18% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Progressive Corp for 81 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| PGR | XBI | |
|---|---|---|
Market Cap | $126.95B | $10.11B |
Volume | 2,749,438 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $242.16 | $169.55 |
52-Week Low | $190.40 | $104.99 |
Typical Hold Time | 81 Days | 37 Days |
Enterprise Value | $135.16B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Progressive Corporation (PGR) trades at $218.51, up 2.05% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with 12.85% net income margin and 34.94% ROE, supported by consistent revenue growth from $49.6B in 2022 to $87.6B in 2025. Recent earnings beat expectations in Q2 2026 with EPS of $4.85 versus $4.64 expected, though Q1 2026 slightly missed. Analyst consensus price target is $222.23 with 38.1% buy ratings.
PGR presents a favorable risk-reward profile with upside to consensus targets, though near-term overbought RSI conditions warrant caution. The insurance giant's telematics advantage and underwriting discipline provide competitive moat, while intensifying auto insurance competition represents the primary business risk. Current valuation at 10.97 P/E appears reasonable given growth trajectory and profitability metrics.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
